EU expands approval of Janssen-Cilag's prostate cancer drug Zytiga

01/15/2013 | PharmaTimes (U.K.)

The European Commission approved the use of Janssen-Cilag's Zytiga, or abiraterone acetate, in combination with prednisolone or prednisone, for patients with metastatic castration-resistant prostate cancer who do not respond to androgen deprivation and for whom chemotherapy is not indicated. The drug's approval in the U.S. was expanded recently to include men with metastatic castration-resistant prostate cancer before chemotherapy.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI